TCPWM
ONCT

Traverso Chambers Private Wealth Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Traverso Chambers Private Wealth Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-500
Closed -$11K – 112
2022
Q2 		$11K Buy
+500
New +$11.1K ﹤0.01% 106
2022
Q1 		– Sell
-600
Closed -$27K – 112
2021
Q4 		$27K Buy
+600
New +$40.4K 0.01% 110

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
BC
BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Traverso Chambers Private Wealth Management's ONCT Position: Q3 2022 in Review

Traverso Chambers Private Wealth Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2022, closing a stake of 500 shares — an estimated $11K sold.

Traverso Chambers Private Wealth Management first reported a position in ONCT in Q4 2021 and held it in 2 quarters. The position peaked at $27K in Q4 2021. 61 funds tracked by Wall St. Rank hold ONCT as of Q3 2022.

  • Traverso Chambers Private Wealth Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Traverso Chambers Private Wealth Management sold 500 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $11K.
  • Traverso Chambers Private Wealth Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Traverso Chambers Private Wealth Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $27K in Q4 2021.
  • 61 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Traverso Chambers Private Wealth Management's 13F filing for Q3 2022, filed 12 Oct 2022.